First Quadrant L P CA decreased its position in Charles River Laboratories Intl. Inc (NYSE:CRL) by 88.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,010 shares of the medical research company’s stock after selling 45,020 shares during the period. First Quadrant L P CA’s holdings in Charles River Laboratories Intl. were worth $541,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Norges Bank bought a new stake in shares of Charles River Laboratories Intl. during the fourth quarter worth $53,008,000. Marshall Wace LLP raised its stake in shares of Charles River Laboratories Intl. by 1,058.9% in the fourth quarter. Marshall Wace LLP now owns 469,045 shares of the medical research company’s stock worth $35,737,000 after buying an additional 428,573 shares in the last quarter. Assenagon Asset Management S.A. bought a new stake in shares of Charles River Laboratories Intl. during the fourth quarter worth $27,886,000. Russell Investments Group Ltd. bought a new stake in shares of Charles River Laboratories Intl. during the fourth quarter worth $24,845,000. Finally, Alyeska Investment Group L.P. raised its stake in Charles River Laboratories Intl. by 43.0% in the fourth quarter. Alyeska Investment Group L.P. now owns 846,324 shares of the medical research company’s stock worth $64,481,000 after buying an additional 254,519 shares in the last quarter. Institutional investors own 95.32% of the company’s stock.

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Shares of Charles River Laboratories Intl. Inc (NYSE:CRL) traded up 0.40% during midday trading on Friday, reaching $89.76. 44,743 shares of the company’s stock traded hands. Charles River Laboratories Intl. Inc has a 12 month low of $67.20 and a 12 month high of $92.61. The stock has a 50 day moving average of $89.03 and a 200-day moving average of $82.35. The stock has a market cap of $4.28 billion, a P/E ratio of 26.27 and a beta of 0.99.

Charles River Laboratories Intl. (NYSE:CRL) last issued its quarterly earnings data on Wednesday, May 10th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.14 by $0.15. The business had revenue of $445.80 million for the quarter, compared to the consensus estimate of $437.04 million. Charles River Laboratories Intl. had a net margin of 9.05% and a return on equity of 25.75%. The company’s quarterly revenue was up 25.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.98 EPS. On average, equities research analysts forecast that Charles River Laboratories Intl. Inc will post $5.10 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Charles River Laboratories Intl. Inc (CRL) Stake Reduced by First Quadrant L P CA” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/05/19/first-quadrant-l-p-ca-sells-45020-shares-of-charles-river-laboratories-intl-inc-crl-updated.html.

A number of research firms have commented on CRL. Citigroup Inc reaffirmed a “neutral” rating and set a $104.00 target price (up previously from $90.00) on shares of Charles River Laboratories Intl. in a report on Thursday, May 11th. Barclays PLC set a $90.00 target price on shares of Charles River Laboratories Intl. and gave the stock a “hold” rating in a report on Saturday, May 13th. Finally, Jefferies Group LLC reissued a “buy” rating on shares of Charles River Laboratories Intl. in a report on Thursday, March 16th. Six investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $88.06.

In related news, Director George Massaro sold 1,130 shares of the stock in a transaction dated Friday, May 12th. The shares were sold at an average price of $88.30, for a total transaction of $99,779.00. Following the sale, the director now directly owns 15,831 shares of the company’s stock, valued at approximately $1,397,877.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider David P. Johst sold 34,593 shares of the stock in a transaction dated Friday, March 10th. The shares were sold at an average price of $89.06, for a total transaction of $3,080,852.58. Following the sale, the insider now directly owns 201,005 shares in the company, valued at $17,901,505.30. The disclosure for this sale can be found here. Insiders sold a total of 73,112 shares of company stock worth $6,484,138 over the last ninety days. Insiders own 2.30% of the company’s stock.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

5 Day Chart for NYSE:CRL

Receive News & Stock Ratings for Charles River Laboratories Intl. Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. Inc and related stocks with our FREE daily email newsletter.